Autolus Therapeutics Reports Second Quarter 2026 Financial Results And Business Updates
AUTL•Second-quarter results and updated guidance
Autolus Therapeutics PLC reported second quarter 2026 financial results and business updates.
- Autolus Therapeutics increased its FY2026 net product revenue guidance to $140 million to $150 million.
- Q2 2026 net product revenue was $45.70 million, versus $20.90 million in Q2 2025.
- Q2 2026 net loss was $39.10 million, versus $47.90 million in Q2 2025.
